AK146D1 for injection: AK146D1 for injection is an antiTrop2/Nectin4 bispecific antibody-drug conjugate
AK112 Injection: AK112 Injection is a PD-1/VEGF bispecific antibody
Study summary
This is a Phase II clinical study aimed at evaluating the safety, tolerability, antitumor efficacy, PK and immunogenicity of AK146D1 monotherapy or combined with AK112 in advanced Urothelial carcinoma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Be able to understand and voluntarily sign the written informed consent form.
* Age 18-75.
* ECOG PS 0 or 1.
* Expected lifespan ≥3 months.
* Histologically or cytologically documented Urothelial carcinoma.
* At least one measurable lesion according to RECIST v1.1.
* Sufficient organ function.
Exclusion Criteria:
* Having other active malignancies within 3 years.
* Currently participating in another interventional clinical study.
* Presence of active metastases to the central nervous system.
* Prior chemotherapy agent targeting topoisomerase I .
* Receipt of systemic anti-tumor therapy within 4 weeks prior to the first dose.
* Patients with clinically significant cardiovascular or cerebrovascular diseases or risks.
* Patients with active autoimmune diseases requiring systemic treatment within 2 years.
* Receipt of systemic anti-infective therapy within 2 weeks prior to the first dose.
* Previous history of severe hypersensitivity reactions.
* Patients with a history of mental illness and incapacitated or limited capacity.
* Any disease or condition that, in the opinion of the investigator, would compromise patient safety or interfere with study assessments.
Primary outcome measure(s)
Number of participants with dose limiting toxicities(DLTs) — During the first 3 weeks of treatment DLTs are defined as toxicities that meet predefined severity criteria, and assessed as having a suspected relationship to study drug
Objective Response Rate(ORR) — Up to 2 years ORR is the proportion of participants with complete response(CR) or partial response(PR)
Number of participants with adverse events (AEs) — From the time of informed consent signed through 90 days after the last dose AEs refer to any untoward medical occurrence or deterioration of existing medical events after the participants sign the ICFs, whether or not considered related to the study treatment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.